[5]Nicholas C. Turner. Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.Doi.10.1200 / JCO.2018.36.15_suppl....
IBRANCE Phase 3 PALOMA-3 trial meets primary endpoint
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients Parcin...
Turner. Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. Doi.10.1200 / JCO.2018.36.15_suppl.1001. [7] Cristofanilli M, Slamon DJ, Ro J, et al. Overall ...
et al.Fulvestrant plus Palbociclib versus Fulvestrant plus placebo for treatment of hormone-receptorpositive,HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3):Final analysis of the multicentre,double-blind,phase 3 randomised controlled trial[J].Lancet Oncol,2016...
Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that p... Background: Endocrine therapy (ET) resistance remains ...
et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Onc...
[5]Nicholas C. Turner. Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.Doi.10.1200 / JCO.2018.36.15_suppl.1001. ...
A novel analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and provides an option for efficacy assessments that could accelerate drug approvals.doi:10.1200/JCO.2022.40.16_suppl.106932111069#Background:Advances in breast cancer (BC) therapy the past few decades have ...
et al.Fulvestrant plus Palbociclib versus Fulvestrant plus placebo for treatment of hormone-receptorpositive,HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3):Final analysis of the multicentre,double-blind,phase 3 randomised controlled trial[J].Lancet Oncol,2016...